{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TXG","limit":50},"count":50,"signals":[{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":100,"match_count":14,"context":"and hire new ones. In August 2022 we conducted a reduction in force in order to decrease costs and maintain a streamlined organization to support our business and in December 2023, we committed to a restructuring plan related to the closure of one of our research and development facilities. We conducted additional reductions in force in 2025 to decrease costs and adjust our organizational structure to align with o","filed_date":"2026-02-13","accession":"0001628280-26-007822","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"es, seasonal or other spending patterns or the operations of our customers or the institutions that fund them, could adversely affect our sales and financial performance. | | | | 15Table of ContentsA substantial portion of our revenue is derived from sales to academic institutions, research organizations and other entities that rely heavily on U.S. academic and government funding, including grants from the NIH and other government","filed_date":"2026-02-13","accession":"0001628280-26-007822","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":89,"context":"ions in U.S. academic and government funding, or modifications of the terms or conditions of funding, they may reduce, delay or cancel their purchases of our products and services, which could have a material adverse effect on our business, financial condition and results of operations. Any changes in U.S. academic and government regulations, policies or operations that affect the terms of research funding could impact","filed_date":"2026-02-13","accession":"0001628280-26-007822","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007822.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"to the budgets, budget cycles, seasonal or other spending patterns or the operations of our customers or the institutions that fund them, could adversely affect our sales and financial performance.A substantial portion of our revenue is derived from sales to academic institutions, research organizations and other entities that rely heavily on U.S. academic and government funding, including grants from the NIH and other government","filed_date":"2025-05-09","accession":"0001770787-25-000032","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":46,"context":".S. academic and government funding, or modifications of the terms or conditions of funding, they may reduce, delay or cancel entirely their purchases of our products and services, which could have a material adverse effect on our business, financial condition and results of operations. 27Table of ContentsAny changes in U.S. academic and government regulations, policies or operations that affect the terms of research fu","filed_date":"2025-05-09","accession":"0001770787-25-000032","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"r, on or following the date on which such initial award is granted, of February 21, May 21, August 21 or November 21 following the initial award grant date and thereafter vest in equal quarterly installments for the following two years.Effective April 26, 2024, each non-employee director who serves on the Board as of the date of any annual meeting of the companys stockholders and will continue to ser","filed_date":"2025-04-14","accession":"0001770787-25-000018","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":64,"context":"LLP as our independent registered public accounting firm for the fiscal year endingDecember 31, 2025; and Proposal Three: a vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers. The board of directors recommends that you vote FOR the election of the nominees named in Proposal One of the accompanying proxy statement and FOR each of Proposals Two and Three. Information about","filed_date":"2025-04-14","accession":"0001770787-25-000018","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"who rely heavily on government funding, including NIH grants, and any reduction in, modification of the terms of or delay in such funding could adversely affect our sales and financial performance.A substantial portion of our revenue is derived from sales to academic institutions, research organizations and other entities that rely heavily on government funding, including grants from the National Institutes of Health (NIH) and ot","filed_date":"2025-02-13","accession":"0001770787-25-000013","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":88,"context":"xperience reductions or delays in government funding, or modifications of the terms or conditions of funding, they may reduce or delay their purchases of our products and services, which could have a material adverse effect on our business, financial condition and results of operations. Any changes in government regulations or policies that affect the terms of research funding could impact our customers ability to secur","filed_date":"2025-02-13","accession":"0001770787-25-000013","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":45,"context":"e of the non-employee director awardees initial election or  | | | 10X GENOMICS, INC. | 20 | 2024 PROXY STATEMENT | | appointment to our board of directors and thereafter vested in equal monthly installments for the following two years. Each initial award of restricted stock units shall have vested as to one-third of such award on the first anniversary of the first to occur, on or following the date","filed_date":"2024-04-26","accession":"0001770787-24-000029","full_text":"https://origin.rootz.global/static/filing/0001770787-24-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":74,"context":"s such that the bylaws may be amended by the board of directors without requiring stockholder approval; and Proposal Four: a vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers. The board of directors recommends that you vote FOR the election of the nominee named in Proposal One of the accompanying proxy statement and FOR each of Proposals Two, Three and Four. Information","filed_date":"2024-04-26","accession":"0001770787-24-000029","full_text":"https://origin.rootz.global/static/filing/0001770787-24-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, Central America, South America, the Middle East","filed_date":"2024-02-15","accession":"0001770787-24-000017","full_text":"https://origin.rootz.global/static/filing/0001770787-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":99,"context":"capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business and operating results.Our success depends on our ability to develop new products and applications for our technology while improving the performance and cost-effectiveness of our exis","filed_date":"2024-02-15","accession":"0001770787-24-000017","full_text":"https://origin.rootz.global/static/filing/0001770787-24-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":38,"context":"one-third of such award on the first anniversary of the date of the non-employee director awardees initial election or appointment to our board of directors and thereafter vest in equal monthly installments for the following two years. Each initial award of restricted stock units shall vest as to one-third of such award on the first anniversary of the first to occur, on or following the date on whic","filed_date":"2023-04-28","accession":"0001770787-23-000021","full_text":"https://origin.rootz.global/static/filing/0001770787-23-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":78,"context":"LLP as our independent registered public accounting firm for the fiscal year endingDecember 31, 2023; and Proposal Three: a vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers. The Board recommends that you vote FOR the election of each of the nominees named in Proposal One of the accompanying proxy statement and FOR each of Proposals Two and Three. Information about the","filed_date":"2023-04-28","accession":"0001770787-23-000021","full_text":"https://origin.rootz.global/static/filing/0001770787-23-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2023-02-16","accession":"0001770787-23-000012","full_text":"https://origin.rootz.global/static/filing/0001770787-23-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":55,"context":"equipment malfunctions, aging components, quality issues with components and materials sourced from third-party suppliers, or failures to strictly follow procedures or meet specifications, may have a material adverse effect on our brand, business, financial condition and operating results and could result in us or our third-party manufacturers losing ISO quality management certifications. If we or our third-party manufa","filed_date":"2023-02-16","accession":"0001770787-23-000012","full_text":"https://origin.rootz.global/static/filing/0001770787-23-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"one-third of such award on the first anniversary of the date of the non-employee director awardees initial election or appointment to our board of directors and thereafter vest in equal monthly installments for the following two years. Each initial award of restricted stock units shall vest as to one-third of such award on the first anniversary of the first to occur, on or following the date on whic","filed_date":"2022-04-29","accession":"0001770787-22-000022","full_text":"https://origin.rootz.global/static/filing/0001770787-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":77,"context":"ng LLP as our independent registered public accounting firm for the fiscal year endingDecember 31, 2022 and Proposal Three a vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers. The Board recommends that you vote FOR the election of each of the nominees named in Proposal One of the accompanying proxy statement and FOR each of Proposals Two and Three. Information about the","filed_date":"2022-04-29","accession":"0001770787-22-000022","full_text":"https://origin.rootz.global/static/filing/0001770787-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2022-02-18","accession":"0001770787-22-000015","full_text":"https://origin.rootz.global/static/filing/0001770787-22-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":53,"context":"equipment malfunctions, aging components, quality issues with components and materials sourced from third-party suppliers, or failures to strictly follow procedures or meet specifications, may have a material adverse effect on our brand, business, financial condition and operating results and could result in us or our third-party manufacturers losing ISO quality management certifications. If we or our third-party manufa","filed_date":"2022-02-18","accession":"0001770787-22-000015","full_text":"https://origin.rootz.global/static/filing/0001770787-22-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2021-11-05","accession":"0001770787-21-000054","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":34,"context":"we continue to work to secure sufficient equipment and materials to meet anticipated future demand. We continue to carry higher levels of inventory and are monitoring closely whether there will be a material negative impact due to potential future shortages, price increases from suppliers, labor shortages or other supply chain disruptions as well as disruptions to our logistics, shipping and other distribution operation","filed_date":"2021-11-05","accession":"0001770787-21-000054","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000054.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2021-08-06","accession":"0001770787-21-000044","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":34,"context":"work to secure sufficient critical equipment and raw materials to meet anticipated future demand and we continue to carry higher levels of inventory and are monitoring closely whether there will be a material negative impact due to potential future shortages or price increases from suppliers.  While the disruption is currently expected to be temporary, there is considerable uncertainty around its duration. We expect thes","filed_date":"2021-08-06","accession":"0001770787-21-000044","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":37,"context":"tinue to work to secure sufficient critical equipment and raw materials to meet anticipated future demand and we are carrying higher levels of inventory and monitoring closely whether there will be a material negative impact due to potential future shortages or price increases from suppliers. Our customer service teams around the world are operating remotely and remain available to assist our customers and partners as ne","filed_date":"2021-05-07","accession":"0001770787-21-000031","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"us Incentive Plan) of a share of ClassA common stock on the date of grant, which vests as to one-third of such grant on the first anniversary of the date of grant and thereafter in equal monthly installments for the following two years, subject to the non-employee director continuing in service though each such vesting date and an annual grant of options having a grant date fair market value equal to","filed_date":"2021-04-23","accession":"0001770787-21-000024","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":76,"context":"pendent registered public accounting firm for the fiscal year endingDecember 31, 2021 and Proposal 3 an advisory vote on the frequency of future advisory votes to approve the compensation paid to our named executive officers. The Board recommends that you vote FOR the election of each of the nominees named in Proposal 1 of the accompanying proxy statement, FOR the ratification of the appointment of Ernst Young LLP as ou","filed_date":"2021-04-23","accession":"0001770787-21-000024","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"rom the issuance of common stock from the exercise of stock options, partially offset by payments on debt obligations of $0.7million. Concentrations of credit risk As of December31, 2020 and 2019, no single customer represented 10% or more of our accounts receivable balance. There was no single customer, including distributors, that individually exceeded 10% of our revenue during the years ended December31, 2020, 2019 and 2018.","filed_date":"2021-02-26","accession":"0001770787-21-000009","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":39,"context":"equipment malfunctions, aging components, quality issues with components and materials sourced from third-party suppliers, or failures to strictly follow procedures or meet specifications, may have a material adverse effect on our brand, business, financial condition and operating results and could result in us or our third-party manufacturers losing ISO quality management certifications. If we or our third-party manufa","filed_date":"2021-02-26","accession":"0001770787-21-000009","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":36,"context":"have not yet experienced any material supply issues. With respect to raw material supply, we have secured sufficient critical raw materials to meet anticipated future demand and do not anticipate any material negative impact due to potential future shortages or price increases from suppliers in the near term. Our customer service teams around the world are operating remotely and remain available to assist our customers a","filed_date":"2020-08-12","accession":"0001628280-20-012520","full_text":"https://origin.rootz.global/static/filing/0001628280-20-012520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":30,"context":"capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business and operating results.** Our success depends on our ability to develop new products and applications for our technology in existing and new markets, while improving the performance an","filed_date":"2020-05-12","accession":"0001193125-20-140382","full_text":"https://origin.rootz.global/static/filing/0001193125-20-140382.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"s Incentive Plan) of a share of Class A common stock on the date of grant, which vests as to one-third of such grant on the first anniversary of the date of grant and thereafter in equal monthly installments for the following two years, subject to the non-employee director continuing in service though each such vesting date; and | | |  |  |  |  an annual grant of options having a grant date fair mark","filed_date":"2020-04-24","accession":"0001193125-20-119032","full_text":"https://origin.rootz.global/static/filing/0001193125-20-119032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":13,"context":"xchange Act of 1934, as amended (the Exchange Act). In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i) December 31, 2024, (ii) the last day of the fiscal year in which our ann","filed_date":"2020-04-24","accession":"0001193125-20-119032","full_text":"https://origin.rootz.global/static/filing/0001193125-20-119032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"platform_shift","strength":100,"match_count":11,"context":"we believe, based on our internal estimates, we could access approximately $13 billion of the global life sciences research tools market. We believe we can further drive growth across our current and adjacent markets by improving or enabling new uses and applications of existing tools and technologies, as our solutions allow researchers to answer questions that may be impractical or impossible to address using e","filed_date":"2020-02-27","accession":"0001193125-20-052640","full_text":"https://origin.rootz.global/static/filing/0001193125-20-052640.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":26,"context":"capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business and operating results.** Our success depends on our ability to develop new products and applications for our technology in existing and new markets, while improving the performance an","filed_date":"2020-02-27","accession":"0001193125-20-052640","full_text":"https://origin.rootz.global/static/filing/0001193125-20-052640.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":21,"context":"gent kits. A significant disruption in the operations of the contract manufacturer or suppliers may impact the production of the Companys products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations.  **Concentrations** Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts","filed_date":"2019-11-12","accession":"0001193125-19-289931","full_text":"https://origin.rootz.global/static/filing/0001193125-19-289931.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"al to the greater of *The Wall Street Journal* prime rate plus 2.0% or 6.25% per annum. Monthly payments of interest are due on the term loan through December 31, 2019, after which equal monthly installments of principal and interest are due. The revolving line of credit terminates on December 1, 2022 and the amount available under the revolving line of credit is based on 80% of eligible receivables","filed_date":"2019-09-10","accession":"0001193125-19-241454","full_text":"https://origin.rootz.global/static/filing/0001193125-19-241454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"platform_shift","strength":100,"match_count":11,"context":"we believe, based on our internal estimates, we could access approximately $13 billion of the global life sciences research tools market. We believe we can further drive growth across our current and adjacent markets by improving, or enabling new uses and applications of, existing tools and technologies, as our solutions allow researchers to answer questions that may be impractical or impossible to address using","filed_date":"2019-09-10","accession":"0001193125-19-241454","full_text":"https://origin.rootz.global/static/filing/0001193125-19-241454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, South America, the Middle East and Africa. As a result,","filed_date":"2019-09-10","accession":"0001193125-19-241454","full_text":"https://origin.rootz.global/static/filing/0001193125-19-241454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_factor","strength":100,"match_count":25,"context":"capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business and operating results; | | |  |  |  If our existing and new products fail to achieve and sustain sufficient scientific acceptance, we will not generate expected revenue and our prospe","filed_date":"2019-09-10","accession":"0001193125-19-241454","full_text":"https://origin.rootz.global/static/filing/0001193125-19-241454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ion titled *Executive compensationDirector compensation*.  143  [Table of Contents](#toc) **Executive compensation** The following table sets forth information concerning the compensation paid to our named executive officers (NEO), during our fiscal year ended December 31, 2018 (fiscal year 2018). Our NEOs for the summary compensation table include our Chief Executive Officer (CEO) and our next two most highly compensat","filed_date":"2019-09-10","accession":"0001193125-19-241454","full_text":"https://origin.rootz.global/static/filing/0001193125-19-241454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":98,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2021-05-07","accession":"0001770787-21-000031","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000031.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":91,"match_count":2,"context":"e of common stock from the exercise of stock options, partially offset by payments of capital lease obligation of $0.4 million.  **Concentrations of credit risk** As of December 31, 2019 and 2018, no single customer represented 10% or more of our accounts receivable balance. There was no single customer, including distributors, that individually exceeded 10% of our revenue during the years ended December 31, 2019, 2018 and 2017","filed_date":"2020-02-27","accession":"0001193125-20-052640","full_text":"https://origin.rootz.global/static/filing/0001193125-20-052640.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":86,"match_count":2,"context":"from proceeds from the issuance of convertible preferred stock, net of issuance costs.  26  [Table of Contents](#toc) **Concentrations of credit risk** As of March 31, 2020 and December 31, 2019, no single customer represented 10% or more of our accounts receivable balance. There was no single customer that individually exceeded 10% of our revenue during the three months ended March 31, 2020 and 2019.  **Contractual Obligation","filed_date":"2020-05-12","accession":"0001193125-20-140382","full_text":"https://origin.rootz.global/static/filing/0001193125-20-140382.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":83,"match_count":1,"context":"outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in Asia, certain regions of Europe, Oceania, South America, the Middle East and Africa. As a","filed_date":"2020-08-12","accession":"0001628280-20-012520","full_text":"https://origin.rootz.global/static/filing/0001628280-20-012520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"platform_shift","strength":82,"match_count":9,"context":"future sales of consumables. We expect our instrument sales to continue to grow as we increase penetration in our existing markets and expand into, or offer new features and solutions that appeal to new markets.  We plan to grow our instrument sales in the coming years through multiple strategies including expanding our sales efforts globally and continuing to enhance the underlying technology and applicat","filed_date":"2019-11-12","accession":"0001193125-19-289931","full_text":"https://origin.rootz.global/static/filing/0001193125-19-289931.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"risk_concentration","strength":81,"match_count":2,"context":"of stock options, partially offset by payments of debt obligations of $0.7 million.  35  [Table of Contents](#toc) **Concentrations of credit risk** As of December 31, 2018 and September 30, 2019, no single customer represented 10% or more of our accounts receivable balance. There was no single customer that individually exceeded 10% of our revenue during the three months ended September 30, 2018 and 2019 or for the nine months","filed_date":"2019-11-12","accession":"0001193125-19-289931","full_text":"https://origin.rootz.global/static/filing/0001193125-19-289931.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"restructuring","strength":80,"match_count":10,"context":"and hire new ones. In August 2022 we conducted a reduction in force in order to decrease costs and maintain a streamlined organization to support the business and in December 2023, we committed to a restructuring plan related to the closure of one of our research and development facilities. In order to be successful and build our framework for future growth, we must continue to execute and deliver on our initiativ","filed_date":"2025-02-13","accession":"0001770787-25-000013","full_text":"https://origin.rootz.global/static/filing/0001770787-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TXG","company":"10x Genomics, Inc.","exchange":"Nasdaq","sector":"Laboratory Analytical Instruments","signal_type":"platform_shift","strength":74,"match_count":8,"context":"components; the level of demand for our products, which may vary significantly and result in excess capacity expenses, and our ability to increase penetration in our existing markets and expand into new markets; our ability to successfully integrate new personnel, technology and other assets that we acquire into our company; the timing and amount of expenditures (including success fees) related to litigati","filed_date":"2021-02-26","accession":"0001770787-21-000009","full_text":"https://origin.rootz.global/static/filing/0001770787-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"1b962c3bc9e1f18ff64eba7b2c98c7e7675bcfa827ac07dc20f93f5e0988463b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"cd76f4a3580bdd0e82c566983ed20d599360edac764346e66e55ce27862eed2f","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":60,"hourly_limit":500,"remaining":440,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}